Is the neck circumference an emergent predictor for inflammatory status in obese adults?

International Journal of Clinical Practice

Volumn 67, Issue 3, 2013, Pages 217-224

  Jamar, G ^a   Pisani, L P ^a   Oyama, L M ^a   Belote, C ^a   Masquio, D C L ^a   Furuya, V A ^a   Carvalho Ferreira, J P ^a   Andrade Silva, S G ^a   Damaso A R ^a   Caranti, D A ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ANTHROPOMETRY; ARTICLE; BLOOD SAMPLING; BODY HEIGHT; BODY MASS; CHEST CIRCUMFERENCE; CLINICAL ARTICLE; CLINICAL PRACTICE; DIASTOLIC BLOOD PRESSURE; FEMALE; HIP CIRCUMFERENCE; HUMAN; INFLAMMATION; MALE; NECK CIRCUMFERENCE; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE;

ADIPONECTIN; ADULT; ANTHROPOMETRY; BLOOD PRESSURE; BODY MASS INDEX; FEMALE; HUMANS; INFLAMMATION; LEPTIN; MALE; NECK; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 84874029554     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12041     Document Type: Article

References (57)

1. Gnacińska M, Małgorzewicz S, Guzek M, Lysiak- Szydłowska W, Sworczak K,. Adipose tissue activity in relation to overweight or obesity. Pol J Endocrinol 2010; 61: 0423-104X.
2. Greenberg AS, Obin MS,. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 2006; 83 (2): 461S-5S.
3. Mertens I, Van Gaal LF,. Obesity, haemostasis and the fibrinolytic system. Obes Rev 2002; 3 (2): 85-101.
4. Fain JN,. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediators Inflamm 2010; 7 (4): 2-9
5. Antuna-Puente B, Feve B, Fellahi S, Bastard JP,. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008; 34 (1): 2-11.
6. Trayhurn P, Wood IS,. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92 (3): 347-55.
7. Rocha VZ, Folco EJ,. Inflammatory concepts of obesity. Int J Inflam 2011; 2011: 1-14.
8. Alessi MC, Juhan-Vague I,. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006; 26 (10): 2200-7.
9. Alessi MC, Bastelica D, Morange P, et al., Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000; 49 (8): 1374-80.
10. Chudek J, Wiecek A,. Adipose tissue, inflammation and endothelial dysfunction. Pharmacol Rep 2006; 58: 81-8.
11. Singh P, Peterson TE, Barber KR, et al., Leptin upregulates the expression of plasminogen activator inhibitor-1 in human vascular endothelial cells. Biochem Biophys Res Commun 2010; 392 (1): 47-52.
12. Dâmaso AR, De Piano A, Sanches PL, et al., Hyperinsulinemia in obese adolescents deregulates neuropeptides during weight loss. Peptides 2011; 32: 1384-91.
13. Botton J, Heude B, Kettaneh A, Borys JM, et al., Cardiovascular risk factor levels and their relationships with overweight and fat distribution in children: the Fleurbaix Laventie Ville Sante II Study. Metabolism 2007; 56: 614-22.
14. Meinsinger C, Döring A, Thorand B, Heier M, Löwel H,. Body fat distribution and risk of type 2 diabetes in the general population: are there differences between men and women? The MONICA/KORA Augburg Cohort Satudy. Am J Clin Nutr 2006; 84 (3): 483-9.
15. Balkau B, Deanfield JE, Després JP, Bassand JP, et al., International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 2007; 116 (17): 1942-51.
16. Vasques AC, Rosado L, Rosado G, et al., Anthropometric indicators of insulin resistance. Arq Bras Cardiol, 2010; 95 (1): e14-23.
17. Taylor AE, Ebrahim SE, Bem-Shlomo Yoav, et al., Comparison of the associations of body mass index and measures of central adiposity and fat mass with coronary heart disease, diabetes, and all-cause mortality: a study using data from 4 UK cohorts. Am J Clin Nutr 2010; 91: 547-56.
18. Preis SR, Massaro JM, Hoffmann U, D'Agostino RB, et al., Neck circumference as a novel measure of cardiometabolic risk: The Framingham Heart Study. The Journal of Clinical Endocrinology & Metabolism 2010; 95: 3701-10.
19. Ben-Noun LL, Laor A,. Relationship between changes in neck circumference and cardiovascular risk factors. Exp Clin Cardiol 2006; 11 (1): 14-20.
20. Laakso M, Matilainen V, Keinänen-Kiukaanniemi S,. Association of neck circumference with insulin resistance-related factors. Int J Obes Relat Metab Disord 2002; 26 (6): 873-5.
21. Wilborn C, et al., Obesity: prevalence, theories, medical consequences, management and research directions. J Int Soc Sports Nutr 2005; 2 (2): 4-31.
22. Callaway CW, Chumlea WC, Bouchard C, Himes JH, Lohman TG, Martin AD, et al. (1988) Circumferences. in:, Lohman TG, Roche AF, Martorell R, eds. Anthropometric Standardization Reference Manual. Champaign, IL: Human Kinetics Books, pp. 39-54.
23. Lean M, Lara J, O'Hill J,. Strategies for preventing obesity. BMJ 2006; 333: 959-62.
24. Valdez R,. A simple model-based index of abdominal adiposity. J Clin Epidemiol 1991; 44 (9): 955-6.
25. Bergman NB, Stefanovski D, Buchanan TA, et al., A better index of body adiposity. Obesity 2011; 19 (5): 1083-9.
26. Brazilian Society of Cardiology (SBC). VI Brazilian Guidelines on the Arterial hypertension. Arq Bras Cardiol 2010; 95 (1): 1-51.
27. Ho SY, Lam TH, Janus ED,. Waist to stature ratio is more strongly associated with cardiovascular risk factors than other simple anthropometric indices. Ann Epidemiol 2003; 13 (10): 683-91.
28. Ben-Noun LL, Laor A,. Relationship of neck circumference to cardiovascular risk factors. Obe Res 2003; 11: 226-31.
29. Ben-Noun LL, Sohar E, Laor A,. Neck circumference as a simple screening measure for identifying overweight and obese patients. Obes Res 2001; 9: 470-7.
30. Lou DH, Yin FZ, Wang R, et al., Neck circumference is an accurate and simple index for evaluating overweight and obesity in Han children. Ann Hum Biol 2012; 39 (2): 161-5.
31. Hingorjo MR, Qureshi MA, Mehdi A,. Neck circumference as a useful marker of obesity: a comparison with body mass index and waist circumference. J Park Med Assoc 2012; 62 (1): 36-40.
32. Ben-Noun LL, Laor A,. Relationship between changes in neck circumference and changes in blood pressure. Am J Hypertens 2004; 17: 409-14.
33. Xiaofan G, Yang L, Guozhe S, et al., Prehypertension in children and adolescents: association with body weight and neck circumference. Intern Med 2012; 51: 23-7.
34. Chagas P, Caramori P, Barcellos C, et al., Association of different anthropometric measures and índices with coronary atherosclerotic burden. Arq Bras Cardiol 2011; 97 (5): 397-401.
35. Medeiros CAM, Bruin VMS, Castro-Silva C, et al., Neck circumference, a bedside feature related to mortality of acute ischemic stroke. Rev Assoc Med Bras 2011; 57 (5): 559-64.
36. Cesari M, Pahor M, Incalzi RA,. Plasminogen activator inhibitor-1 (PAI-1): a key fator linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther 2010; 28: e72-91.
37. Brazilian Society of Cardiology. Guidelines on obesity. Arq Bras Cardiol 2002; 78: 1-13.
38. Sanches LP, De Mello MT, Elias N, Fonseca FA, et al., Improvement in HOMA-IR is na independente predictor of reduced carotid intima-media thickness in obese adolescents participating in na interdisciplinary weight-loss program. Hypertens Res 2011; 34 (2): 232-8.
39. Gramling MW, Church FC,. Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. Thromb Res 2010; 125 (5): 377-81.
40. Shimomura I, Funahashi T, Takahashi M, et al., Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2: 800-3.
41. Mavri A, Alesse MC, Bastelica D, et al., Subcutaneous abdominal, but not femoral fat expression. Of plasminogen activator inhibitor (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia 2001; 44: 2025-31.
42. Hajer GR, Haeften TW, Visseren FLJ,. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008; 29: 2959-71.
43. Loskutoff DJ, Samad F,. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol 1998; 18 (1): 1-6.
44. Folsom AR, Qamhieh HT, Wing RR, Jeffery RW, et al., Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb Vasc Biol 1993; 13: 162-9.
45. Pisani LP, Oyama LM, Bueno AA, Biz C, et al., Hydrogenated fat intake during pregnancy and lactation modifies serum lipid profile and adipokine mRNA in 21-day-old rats. Nutrition 2008; 24 (3): 255-61.
46. Zhang H, Cui J, Zhang C,. Emerging role of adipokines as mediators in atherosclerosis. World J Cardiol 2010; 2 (11): 370-6.
47. Lira FS, Rosa JC, Lima-Silva AE, et al., Sedentary subjects have higher PAI-1 and lipoproteins levels than highly trained athletes. Diabetol Metab Syndr 2010; 22 (2): 7.
48. Brazilian Society of Cardiology. IV Brazilian Guidelines on Dyslipidemias and Atherosclerosis Prevention. Arq Bras Cardiol 2007; 88 (1): 2-19.
49. Vague P, Juhan-Vague I, Aillaud MF, et al., Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma, insulin level, and relative body weight in normal and obese subjects. Metabolism 1986; 35: 250-3.
50. Lakka HM, Lakkasonen DE, Lakka TA, et al., The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16.
51. Isomaa B, Almgren P, Tuomi T, et al., cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
52. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM,; Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51 (4): 1131-7.
53. Alberti KG, Zimmet P, Shaw J, (IDF) IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-62.
54. You T, Nicklas BJ, Ding J, et al., The metabolic syndrome is associated with circulating adipokines in older adults across a wide range of adiposity. J Gerontol A Biol Sci Med Sci 2008; 63: 414-9.
55. Jung CH, Rhee EJ, Choi JH, Bae JC, et al., The relationship of adiponectin/leptin ratio with homeostasis model assessment insulin resistance index and metabolic syndrome in apparently healthy Korean male adults. Korean Diabetes J 2010; 34 (4): 237-43.
56. Lee JM, Kim SR, Yoo SJ, Hong OK, et al., The relationship between adipokines, metabolic parameters and insulin resistance in patients with metabolic syndrome and type 2 diabetes. J Int Med Res 2009; 37: 1803-12.
57. Corgosinho FC, de Piano A, Sanches PL, Campos RM, et al., The role of PAI-1 and adiponectin on the inflammatory state and energy balance in obese adolescents with metabolic syndrome. Inflammation 2012; 35 (3): 944-51.